BioSpace News Archive

Akoya Biosciences, Inc., The Spatial Biology Company™, announced today that an in-depth comparison of immuno-oncology biomarker types conducted by scientists at Johns Hopkins University, Yale University, and other institutions

SNA International, LLC is proud to announce that we have been named the U.S. Small Business Administration (SBA)'s 2019 Region III Small Business Prime Contractor of the Year.

Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces it has received the approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with a Phase 1/2a clinical trial of TG6002 administered by intrahepatic artery (IHA) infusion in colorectal cancer patients with unresectable liver metastases (CRLM).

Peak Health Center, a 501(c)(3), not-for-profit California corporation, announces the release of Diabet - a 100% natural, plant-based supplement that shows breakthrough potential for supporting healthy blood sugar levels.

The National Association of Professional Insurance Agents (PIA National) praised the overwhelming passage in the U.S. House of a bipartisan bill to repeal the provision of the Affordable Care Act (ACA) known to many as the “Cadillac Tax.”

Centinel Spine, LLC, the largest privately-held spine company focused on anterior column reconstruction, today announced that it received Investigational Device Exemption (IDE) approval from the Food and Drug Administration (FDA) to initiate a two-level clinical trial with two different prodisc® C Anterior Cervical Total Disc devices - prodisc C Vivo and prodisc C SK.

From the microcosm to the telecosm to the cryptocosm, technology economist George Gilder has been at the leading edge of internet architecture for over 30 years

Manhattan Scientifics Inc.’s (OTC: QB MHTX) former wholly-owned subsidiary that was initially funded by MHTX, Imagion Biosystems Ltd (ASX:IBX) over a nine-year period has received confirmation from the Food and Drug Administration (FDA) that the MagSense System and Test for staging HER2 breast cancer has qualified for and been granted designation as a breakthrough device

Pharmazz, Inc., today announced that it has received permission to initiate a prospective, multicentric, randomized, double-blind, parallel, phase III clinical study to assess efficacy of PMZ-1620 along with standard treatment in patients of acute ischemic stroke in India.

Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorization Application (MAA) for avapritinib for the treatment of adult patients with PDGFRα D842V mutant gastrointestinal stromal tumors (GIST), regardless of prior therapy, and fourth-line GIST.